133 related articles for article (PubMed ID: 37778345)
1. Effects of Early Short-Course Corticosteroids on Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
Huang DD; Liao BC; Hsu WH; Yang CY; Lin YT; Wu SG; Tsai TH; Chen KY; Ho CC; Liao WY; Shih JY; Yu CJ; Yang JC; Cheng AL; Shen YC
Oncology; 2024; 102(4):318-326. PubMed ID: 37778345
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitor-related adverse events: Real-world experience from a single veterans' affairs medical center.
Benz S; Sherman KA; Dasanu CA; Alvarez-Argote J
J Oncol Pharm Pract; 2024 Jun; 30(4):697-704. PubMed ID: 37350125
[TBL] [Abstract][Full Text] [Related]
3. Identification and Characterization of Immune Checkpoint Inhibitor-Induced Toxicities From Electronic Health Records Using Natural Language Processing.
Barman H; Venkateswaran S; Santo AD; Yoo U; Silvert E; Rao K; Raghunathan B; Kottschade LA; Block MS; Chandler GS; Zalis J; Wagner TE; Mohindra R
JCO Clin Cancer Inform; 2024 Apr; 8():e2300151. PubMed ID: 38687915
[TBL] [Abstract][Full Text] [Related]
4. Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non-small cell lung cancer patients.
Torasawa M; Yoshida T; Takeyasu Y; Shimoda Y; Tateishi A; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Takahashi K; Ohe Y
Cancer Med; 2023 Jun; 12(11):12388-12401. PubMed ID: 37062059
[TBL] [Abstract][Full Text] [Related]
5. Rapid identification of inflammatory arthritis and associated adverse events following immune checkpoint therapy: a machine learning approach.
Tran SD; Lin J; Galvez C; Rasmussen LV; Pacheco J; Perottino GM; Rahbari KJ; Miller CD; John JD; Theros J; Vogel K; Dinh PV; Malik S; Ramzan U; Tegtmeyer K; Mohindra N; Johnson JL; Luo Y; Kho A; Sosman J; Walunas TL
Front Immunol; 2024; 15():1331959. PubMed ID: 38558818
[TBL] [Abstract][Full Text] [Related]
6. Corticosteroid administration for cancer-related indications is an unfavorable prognostic factor in solid cancer patients receiving immune checkpoint inhibitor treatment.
Wang Y; Yang M; Tao M; Liu P; Kong C; Li H; Chen Y; Yin X; Yan X
Int Immunopharmacol; 2021 Oct; 99():108031. PubMed ID: 34358857
[TBL] [Abstract][Full Text] [Related]
7. Discontinuation of Immune Checkpoint Inhibitor due to irAEs in NSCLC Patients With EGFR Mutation.
Okauchi S; Miyazaki K; Shiozawa T; Yamada H; Satoh H; Hizawa N
Cancer Diagn Progn; 2023; 3(2):244-250. PubMed ID: 36875301
[TBL] [Abstract][Full Text] [Related]
8. Sarcoid-like reactions to immune checkpoint inhibitors: Incidence, treatment course, and impact on cancer progression and survival.
Smith H; Easterling R; Ma J; Moodabagil M; Meara A; Owen DH; Crouser E; Singha A; Ho K
Respir Med; 2024 Jun; 227():107640. PubMed ID: 38648910
[TBL] [Abstract][Full Text] [Related]
9. Real-world Incidences and Risk Factors of Immune-related Adverse Events in Patients Treated with Immune Checkpoint Inhibitors: A Nationwide Retrospective Cohort Study.
Kim YJ; Lee M; Kim EH; Lee S; Park S; Hong MH; Shin SJ; Jung I; Lee CK; Lee CS
Cancer Lett; 2024 Jun; ():216998. PubMed ID: 38830470
[TBL] [Abstract][Full Text] [Related]
10. Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer.
Akamatsu H; Murakami E; Oyanagi J; Shibaki R; Kaki T; Takase E; Tanaka M; Harutani Y; Yamagata N; Okuda Y; Furuta K; Sugimoto T; Teraoka S; Hayata A; Tokudome N; Ozawa Y; Mori K; Koh Y; Yamamoto N
Oncologist; 2020 Apr; 25(4):e679-e683. PubMed ID: 32297443
[TBL] [Abstract][Full Text] [Related]
11. The Prognostic Significance of the Continuous Administration of Anti-PD-1 Antibody
Fujisaki T; Watanabe S; Ota T; Kushiro K; Sato Y; Takahashi M; Ohtsubo A; Shoji S; Nozaki K; Ichikawa K; Hokari S; Kondo R; Miyabayashi T; Abe T; Miura S; Tanaka H; Okajima M; Terada M; Matsumoto N; Ishida T; Iwashima A; Sato K; Yoshizawa H; Aoki N; Hayashi M; Ohshima Y; Koya T; Kikuchi T
Front Oncol; 2021; 11():704475. PubMed ID: 34631533
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma.
Abou Alaiwi S; Xie W; Nassar AH; Dudani S; Martini D; Bakouny Z; Steinharter JA; Nuzzo PV; Flippot R; Martinez-Chanza N; Wei X; McGregor BA; Kaymakcalan MD; Heng DYC; Bilen MA; Choueiri TK; Harshman LC
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32066646
[TBL] [Abstract][Full Text] [Related]
13. Association Between the Severity of Immune-related Adverse Events and the Prognosis in Patients With Non-small Cell Lung Cancer Receiving Treatment With Immune Checkpoint Inhibitors.
Inomata M; Matsumoto M; Hayashi K; Seto Z; Hirai T; Tokui K; Taka C; Okazawa S; Kambara K; Imanishi S; Miwa T; Hayashi R; Matsui S; Tobe K
Anticancer Res; 2023 Jul; 43(7):3241-3246. PubMed ID: 37351972
[TBL] [Abstract][Full Text] [Related]
14. Risk factors indicating immune-related adverse events with combination chemotherapy with immune checkpoint inhibitors and platinum agents in patients with non-small cell lung cancer: a multicenter retrospective study.
Fujimoto A; Koutake Y; Hisamatsu D; Ookubo N; Yabuuchi Y; Kamimura G; Kai T; Kozono A; Ootsu T; Suzuki H; Matsuo K; Kuwahara K; Oiwane Y; Nagata Y; Tanimoto K; Sato E; Suenaga M; Uehara T; Ikari A; Endo S; Hiraki Y; Kawamata Y
Cancer Immunol Immunother; 2023 Jul; 72(7):2169-2178. PubMed ID: 36849845
[TBL] [Abstract][Full Text] [Related]
15. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Inhibitor Rechallenge Safety and Efficacy in Stage IV Non-Small Cell Lung Cancer Patients After Immune-Related Adverse Events.
Guo M; VanderWalde AM; Yu X; Vidal GA; Tian GG
Clin Lung Cancer; 2022 Dec; 23(8):686-693. PubMed ID: 36050243
[TBL] [Abstract][Full Text] [Related]
17. Impact of concurrent medications on clinical outcomes of cancer patients treated with immune checkpoint inhibitors: analysis of Health Insurance Review and Assessment data.
Hong S; Lee JH; Heo JY; Suh KJ; Kim SH; Kim YJ; Kim JH
J Cancer Res Clin Oncol; 2024 Apr; 150(4):186. PubMed ID: 38600328
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy Outcomes in Immune Checkpoint Inhibitor-Treated Patients With Metastatic Urothelial Carcinoma Requiring Treatment Interruption or Discontinuation Due to Immune-Related Adverse Events.
Nizam A; Rader RK; Tzeng A; Wei W; Sheng IY; Martin A; Wee CE; Gilligan TD; Gupta S; Ornstein MC
Clin Genitourin Cancer; 2024 Apr; 22(2):368-379. PubMed ID: 38245437
[TBL] [Abstract][Full Text] [Related]
19. Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer.
Komiya K; Nakamura T; Abe T; Ogusu S; Nakashima C; Takahashi K; Kimura S; Sueoka-Aragane N
Thorac Cancer; 2019 Sep; 10(9):1798-1804. PubMed ID: 31328416
[TBL] [Abstract][Full Text] [Related]
20. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]